The first-in-human trial saw all three patients able to increase their walking distance within six minutes to 20 meters.

From FDA approvals to medical milestones, here are four key developments from spine and orthopedic medtech companies since Jan. 29.

Kuros Biosciences USA, Inc. announces an exclusive strategic agreement with the Medtronic spinal division 07-Jan-2025 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art.

The global spine biologics market is on pace to have a 17.51% compound annual growth rate from 2024 to 2034, according to a Jan. 31 news release from Researchan ...

The Inceptiv data give Medtronic more evidence as it tries to increase sales of a product that drove double-digit growth at ...

The spinal surgical robots market is experiencing rapid growth as healthcare facilities worldwide adopt robotic-assisted technologies for spine surgeries. These robots enhance precision, reduce ...

Medtronic is capturing demand for its cutting-edge solutions, as recent product launches emerge to drive new growth. With the ...

Medtronic (NYSE: MDT) today announced 12-month data demonstrating the benefits of its Inceptiv closed-loop spinal cord stimulator (CL-SCS).

This was a 7.1% year-over-year growth rate. That was the result of growth in Neuromodulation, Spine and Biologics, and Neurosurgery products. Medtronic's Diabetes segment produced $686 million in ...

The agreement provides Medtronic with exclusivity in certain spine geographies within the U.S. market, underscoring a shared commitment to expanding access to Kuros' pioneering MagnetOs bone ...

Medtronic is capturing demand for its cutting ... models to develop customized patient treatment plans for complex spine and cranial procedures. And in the highly competitive diabetes care segment ...